Sound Pharmaceuticals concludes subject enrolment for SPI-1005 trial

Phase 3SPI-1005Positive

AI Analysis

Summary

Sound Pharmaceuticals has completed subject enrollment for its second Phase III clinical trial of SPI-1005 in adults with probable or definite Meniere's disease. The trial advancement represents progress toward potential regulatory submission.

Clinical Trial Data

Phase

Phase 3

Outcome Details

Subject enrollment completed for second Phase III trial

Importance:5/10

Sentiment:

0.30

clinical trialPhase 3enrollment completionMeniere's disease

Related Companies

$TRAX $ARNA

Read the original article

Published by Clinical Trials Arena on July 15, 2026 9:23 AM

Read Original